文献速递淋巴瘤

霍奇金淋巴瘤初始治疗后淋巴样恶性肿瘤的晚期复发——丹麦淋巴瘤登记研究

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
PubMed 文献 · Br J Haematol · 2022-04-08

该研究分析丹麦淋巴瘤登记中1982至2018年诊断的3350例霍奇金淋巴瘤患者,描述初始治疗后至少5年发生的淋巴样恶性肿瘤晚期复发(LR)模式、危险因素及结局。LR共58例,10、15、20年累积发生率分别为2.7%、4.0%和5.4%;结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)的LR风险更高(HR 4.5),经典型霍奇金淋巴瘤(cHL)中LR与死亡风险近三倍增加相关,约22.4%的LR患者发生第二次复发。

要点

  • LR在NLPHL中更常见,HR 4.5(95%CI 2.4-8.4,p<0.001)。
  • cHL中年龄较大和淋巴细胞减少是LR危险因素,HR分别为1.04/年(95%CI 1.02-1.06)和5.6(95%CI 2.7-11.5)。
  • cHL中LR与死亡风险近三倍增加相关;22.4%的LR患者发生第二次复发。

核心结论

  • 霍奇金淋巴瘤初始治疗后LR虽不常见但持续累积,NLPHL及cHL中特定临床病理特征可识别高风险患者。

研究设计与样本

  • 回顾性队列分析丹麦国家淋巴瘤登记(LYFO)中1982至2018年诊断的3350例霍奇金淋巴瘤患者。

主要发现

  • LR共58例,10、15、20年累积发生率分别为2.7%、4.0%和5.4%。
  • NLPHL患者LR风险更高,HR 4.5(95%CI 2.4-8.4,p<0.001)。
  • cHL中年龄较大和淋巴细胞减少与LR风险相关,HR分别为1.04/年(95%CI 1.02-1.06)和5.6(95%CI 2.7-11.5)。
  • 混合细胞型组织学亚型仅在女性中为LR危险因素,HR 5.4(95%CI 1.4-20.4,p=0.014)。
  • cHL中LR与死亡风险近三倍增加相关;22.4%的LR患者发生第二次复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analysed a large cohort of Hodgkin lymphoma (HL) patients in order to characterize: (1) the pattern of late recurrence of lymphoid malignancies (LR) after initial treatment for HL over a 35-year period; (2) the clinicopathological parameters influencing the risk of LR; and (3) the outcome of patients experiencing LR. We reviewed data of 3350 HL patients diagnosed in Denmark between 1982 and 2018 and registered in the Danish National Lymphoma Registry (LYFO). LR was defined as a recurrence of lymphoid malignancy at least five years after initial diagnosis. LR occurred in 58 patients, with a cumulative incidence at 10, 15 and 20 years of 2.7%, 4.0% and 5.4% respectively. LR was more frequently observed in patients with nodular lymphocyte-predominant HL (NLPHL) [hazard ratio (HR) 4.5; 95% confidence interval (CI): 2.4-8.4, p < 0.001]. In classical HL (cHL) patients, older age and lymphocytopenia were risk factors for LR with HRs of 1.04 per additional year (95% CI: 1.02-1.06) and 5.6 (95% CI: 2.7-11.5) respectively. Mixed cellularity histological subtype was a risk factor for LR, but only in females, with a HR of 5.4 (95% CI: 1.4-20.4, p = 0.014). In contrast to what was observed in NLPHL, LR in cHL was associated with an almost threefold increased risk of death compared with patients in continuous complete remission. Approximately one fifth (22.4%) of patients with LR experienced a second relapse.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Andersen MD, Hamilton-Dutoit S, Modvig L, et al. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry. Br J Haematol. 2022. PMID: 35396711. doi:10.1111/bjh.18180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。